Trial · NCT02355821
Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women
NCT02355821, Not applicable, Completed, National Research Center for Preventive Medicine; results first posted 2021-09-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women. Trials, record NCT02355821. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02355821
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women
- NCT number
- NCT02355821
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 114 participants, actual
- Lead sponsor
- National Research Center for Preventive Medicine
- Conditions
- Osteopenia, Arterial Hypertension
- Interventions
- Moxonidine, Bisoprolol
- First posted
- 2015-02-04
- Last updated
- 2021-09-01
- Results first posted
- 2021-09-01
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Collagen Type 1 C-telopeptide | baseline (Visit 1) and 12 months (Visit 4) | Changes in Median (Inter-Quartile Range) of the bone resorption marker (collagen type 1 C-telopeptide) at the end of the study from the baseline are evaluated in comparison between the groups |
| Secondary | Osteocalcin | baseline (Visit 1) and 12 months (Visit 4) | Changes in Median (Inter-Quartile Range) values of the bone synthesis marker (osteocalcin) at the end of the study (V4) from the baseline (V1) and to compare the values between the groups. |
| Secondary | Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL). | baseline (Visit 1) and 12 months (Visit 4) | Changes in Median (Inter-Quartile Range) values of the receptor activator of nuclear factor kappa-B ligand (RANKL) at final visit versus baseline level in comparison between the groups |
| Secondary | Bone Mineral Density (BMD) Using Control Dual-energy X-ray Absorptiometry | 12 months | Changes in Median (Inter-Quartile Range) values of Bone mineral density (BMD) at final visit versus baseline level using control dual-energy X-ray absorptiometry and in comparison between the groups |
| Secondary | Telomerase Activity | baseline (Visit 1) and 12 months (Visit 4) | Changes in Median (Inter-Quartile Range) telomerase activity at final visit versus baseline level in comparison between the groups Telomerase activity is measured in arbitrary units. Currently, there are no established reference values for telomerase activity in the world. Its activity is considered high or low in relation to the median. |
| Secondary | Pulse Wave Velocity (PWV) | baseline (Visit 1) and 12 months (Visit 4) | Changes in mean pulse wave velocity (PWV) at final visit versus baseline level and in comparison between the groups |
| Secondary | Intima-media Thickness (IMT) | baseline (Visit 1) and 12 months (Visit 4) | Changes in mean intima-media thickness (IMT) at final visit in comparison between the groups. |
| Secondary | THe Number (Percentage) of the Treatment Responders | baseline (Visit 1) and 12 months (Visit 4) | Proportion of the treatment responders (defined as the proportion (%) of patients who achieved target blood pressure \<140/90 mmHg) after 8 and 48 weeks of the investigated treatment (V2, V3 and V4) and to compare the values between the groups. |
| Secondary | Number of Participants With Adverse Events (AE) | baseline (Visit 1) and 12 months (Visit 4) | Number of Participants with Adverse Events (AE) |
Source ClinicalTrials.gov
Outcomes9
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Collagen Type 1 C-telopeptide | baseline (Visit 1) and 12 months (Visit 4) | ng/ml | MEDIAN | |
| SECONDARY | Osteocalcin | baseline (Visit 1) and 12 months (Visit 4) | ng/ml | MEDIAN | |
| SECONDARY | Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL). | baseline (Visit 1) and 12 months (Visit 4) | pmol/ml | MEDIAN | |
| SECONDARY | Bone Mineral Density (BMD) Using Control Dual-energy X-ray Absorptiometry | 12 months | Total hip BMD | g/cm2 | MEDIAN |
| SECONDARY | Telomerase Activity | baseline (Visit 1) and 12 months (Visit 4) | arbitrary units | MEDIAN | |
| SECONDARY | Pulse Wave Velocity (PWV) | baseline (Visit 1) and 12 months (Visit 4) | m/s | MEAN | |
| SECONDARY | Intima-media Thickness (IMT) | baseline (Visit 1) and 12 months (Visit 4) | mm | MEAN | |
| SECONDARY | THe Number (Percentage) of the Treatment Responders | baseline (Visit 1) and 12 months (Visit 4) | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With Adverse Events (AE) | baseline (Visit 1) and 12 months (Visit 4) | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Collagen Type 1 C-telopeptide | Moxonidine | Baseline | 0.4 | Inter-Quartile Range 0.3 to 0.5 | ng/ml |
| Collagen Type 1 C-telopeptide | Bisoprolol | Baseline | 0.4 | Inter-Quartile Range 0.3 to 0.6 | ng/ml |
| Collagen Type 1 C-telopeptide | Moxonidine | 12 months | 0.3 | Inter-Quartile Range 0.2 to 0.4 | ng/ml |
| Collagen Type 1 C-telopeptide | Bisoprolol | 12 months | 0.4 | Inter-Quartile Range 0.3 to 0.5 | ng/ml |
| Osteocalcin | Moxonidine | Baseline | 18.2 | Inter-Quartile Range 12.4 to 21.9 | ng/ml |
| Osteocalcin | Bisoprolol | Baseline | 19.4 | Inter-Quartile Range 12.4 to 26.2 | ng/ml |
| Osteocalcin | Moxonidine | 12 months | 19.6 | Inter-Quartile Range 15.4 to 23.5 | ng/ml |
| Osteocalcin | Bisoprolol | 12 months | 18.7 | Inter-Quartile Range 12.8 to 22.79 | ng/ml |
| Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL). | Moxonidine | Baseline | 0.109 | Inter-Quartile Range 0.06 to 0.18 | pmol/ml |
| Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL). | Bisoprolol | Baseline | 0.133 | Inter-Quartile Range 0.06 to 0.182 | pmol/ml |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Moxonidine | 57 | |
| Overall Study | STARTED | Bisoprolol | 57 | |
| Overall Study | COMPLETED | Moxonidine | 57 | |
| Overall Study | COMPLETED | Bisoprolol | 57 | |
| Overall Study | NOT COMPLETED | Moxonidine | 0 | |
| Overall Study | NOT COMPLETED | Bisoprolol | 0 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | headache | General disorders | Moxonidine | 2 | 57 | 2 |
| other | headache | General disorders | Bisoprolol | 1 | 57 | 1 |
| other | cough | General disorders | Moxonidine | 0 | 57 | 0 |
| other | cough | General disorders | Bisoprolol | 2 | 57 | 2 |
| other | Dry mouth | General disorders | Moxonidine | 1 | 57 | 1 |
| other | Dry mouth | General disorders | Bisoprolol | 0 | 57 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Moxonidine | 0 | 57 |
| Total, all-cause mortality | Bisoprolol | 0 | 57 |
| Total, other adverse events | Moxonidine | 3 | 57 |
| Total, other adverse events | Bisoprolol | 3 | 57 |
| Total, serious adverse events | Moxonidine | 0 | 57 |
| Total, serious adverse events | Bisoprolol | 0 | 57 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Moxonidine vs Bisoprolol: THe Number (Percentage) of the Treatment Responders | Trial comparisons |
| Moxonidine vs Bisoprolol: Number of Participants With Adverse Events (AE) | Trial comparisons |
| Moxonidine vs Bisoprolol: deaths from any cause | Trial comparisons |
| Moxonidine vs Bisoprolol: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02355821
GET https://conductscience.org/api/trials/v1/NCT02355821/results?page=2